Science Explorer Back to mapMap
Discussion
Topic · Molecular Biology

Ubiquitin and proteasome pathways

Ubiquitin and proteasome pathways is a research topic within Molecular Biology. Science Explorer counts 44k research works in it since 1950. 9.9% of them reached the world's top 10% most cited for their field and year.

This cluster of papers focuses on the Ubiquitin-Proteasome Proteolytic Pathway, exploring mechanisms of protein degradation, regulation of E3 Ubiquitin Ligases, roles of Deubiquitinating Enzymes, and the impact of SUMOylation. It also delves into the development of proteasome inhibitors for cancer therapy and the involvement of this pathway in NF-?B activation.

  • Ubiquitin
  • Proteasome
  • Deubiquitinating Enzymes
  • E3 Ubiquitin Ligases
  • SUMOylation
  • Protein Degradation
  • Polyubiquitin Chains
  • Proteasome Inhibitors
  • NF-?B Activation
  • Cancer Therapy
Research works
44k
fractional, since 1950
In the world top 10%
4.4k
per year above
Top-10% rate
9.9%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+13%
the tick is no change
Largest producer
China
44% of the 10 largest, 2022-now
Ubiquitin and proteasome pathways

Which countries lead Ubiquitin and proteasome pathways research?

By volume, China and the United States publish the most (3.2k and 2k works in 2022-now).

By volume, 2022-now

  1. 1 China 3.2k works
  2. 2 United States 2k works
  3. 3 Germany 341 works
  4. 4 Japan 297 works
  5. 5 United Kingdom 289 works
  6. 6 India 273 works
  7. 7 South Korea 197 works
  8. 8 Canada 190 works
  9. 9 France 177 works
  10. 10 Italy 177 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

China: 44.5%United States: 28.3%Germany: 4.8%Japan: 4.2%6 others listed: 18.3%44%largest
China3,169 · 44.5%United States2,017 · 28.3%Germany341 · 4.8%Japan297 · 4.2%6 others listed1,303 · 18.3%

Shares of the rows listed above, not of the whole node.

Which institutions lead Ubiquitin and proteasome pathways research?

By volume in 2022-now, Harvard University publishes the most Ubiquitin and proteasome pathways research, followed by Chinese Academy of Sciences and Zhejiang University.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 115 works
  2. 2 Chinese Academy of SciencesChina 102 works
  3. 3 Zhejiang UniversityChina 85 works
  4. 4 Shanghai Jiao Tong UniversityChina 84 works
  5. 5 Sun Yat-sen UniversityChina 78 works
  6. 6 National Institutes of HealthUnited States 65 works
  7. 7 Central South UniversityChina 62 works
  8. 8 Nanjing Medical UniversityChina 62 works
  9. 9 Sichuan UniversityChina 54 works
  10. 10 Centre National de la Recherche ScientifiqueFrance 54 works

Who are the leading researchers in Ubiquitin and proteasome pathways?

The most-cited researchers publishing on Ubiquitin and proteasome pathways include Eric S. Lander, Mark J. Daly and Stacey L. Gabriel.

  1. 1 Eric S. Lander United States 524k citations
  2. 2 Mark J. Daly United States 403k citations
  3. 3 Stacey L. Gabriel United States 402k citations
  4. 4 Peer Bork Germany 396k citations
  5. 5 Guido Kroemer France 386k citations
  6. 6 Bert Vogelstein United States 373k citations
  7. 7 Gad A. Getz United States 364k citations
  8. 8 Elaine R. Mardis United States 346k citations
  9. 9 Shizuo Akira Japan 342k citations
  10. 10 Jun Wang China 340k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Ubiquitin and proteasome pathways?

The most cited paper in Ubiquitin and proteasome pathways is "THE UBIQUITIN SYSTEM" (Avram Hershko, Aaron J. Ciechanover, 1998), with 8,852 citations. Next come "A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes" (8,489) and "p53, the Cellular Gatekeeper for Growth and Division" (7,766).

Most cited papers
#PaperReleasedCitations
1 THE UBIQUITIN SYSTEM Avram Hershko, Aaron J. Ciechanover · Annual Review of Biochemistry Review Jun 1998 8,852
2 A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Marcy E. MacDonald · Cell Open access Mar 1993 8,489
3 p53, the Cellular Gatekeeper for Growth and Division Arnold J. Levine · Cell Open access Feb 1997 7,766
4 LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing Yukihiro Kabeya, Noboru Mizushima, Takashi Ueno et al. · The EMBO Journal Open access Nov 2000 6,650
5 CDK inhibitors: positive and negative regulators of G1-phase progression Charles J. Sherr, Joanna Roberts · Genes & Development Open access 15 Jun 1999 6,153
All 100 most cited papers, with filters and sorting

Where is Ubiquitin and proteasome pathways research done?

The largest centres of Ubiquitin and proteasome pathways research in 2022-now are Beijing (China), Shanghai (China), Guangzhou (China) and Hangzhou (China). Among places with at least 20 works in it, it is an unusually large share of all research in Dundee and Nantong.

Largest cities, 2022-now

  1. 1 BeijingChina 322 works
  2. 2 ShanghaiChina 276 works
  3. 3 GuangzhouChina 201 works
  4. 4 HangzhouChina 165 works
  5. 5 NanjingChina 149 works
  6. 6 WuhanChina 141 works
  7. 7 ChangshaChina 101 works
  8. 8 New YorkUnited States 100 works
  9. 9 SeoulSouth Korea 91 works
  10. 10 JinanChina 91 works

Where it is the local speciality

  1. DundeeGB · 28.1 works15×
  2. NantongCN · 30.9 works8.1×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Ubiquitin and proteasome pathways than the world average.

See Ubiquitin and proteasome pathways on the map

Where is the best place to study Ubiquitin and proteasome pathways?

Among universities, judged by research, Harvard University, China Pharmaceutical University and University of Dundee score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%10%20%mean 16.33%fractional works in this field (log) →share of work in the world top 10% →China Pharmaceutical…Harvard UniversityUniversity of DundeeSun Yat-sen University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 82.218.5%5.0×115 -3.8%
2China Pharmaceutical UniversityChina 73.320.7%23.9×38 +101.9%
3University of DundeeUnited Kingdom 73.117.9%22.1×28 +3.7%
4Sun Yat-sen UniversityChina 67.616.7%5.2×78 +30.0%
5Zhejiang UniversityChina 64.512.3%4.4×85 +45.1%
6Sichuan UniversityChina 64.017.2%3.4×54 +53.9%
7Peking UniversityChina 60.316.7%3.6×52 +8.5%
8Nanjing Medical UniversityChina 59.912.3%9.7×62 +56.5%
9Wuhan UniversityChina 59.712.2%5.2×53 +49.0%
10Nanjing University of Chinese MedicineChina 57.518.8%9.2×17 +144.1%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Ubiquitin and proteasome pathways, country by country

Is Ubiquitin and proteasome pathways research growing?

Output in 2022-2025 was 13% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Ubiquitin and proteasome pathways.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Ubiquitin and proteasome pathways as a percentage of every work published that year, 0.036% in 2024.

still counting0.020%0.040%0.060%Ubiquitin and proteasome pathways0.035% in 202519801990200020102020

Fractional works of Ubiquitin and proteasome pathways over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Ubiquitin and proteasome pathways9.9% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Ubiquitin and proteasome pathways. Posts are plain text and can be reported.